Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
Open Access
- 1 April 2013
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 13 (6) , 760-773
Abstract
Abstract: Tyrosine kinases (TK) are enzymes capable of transferring phosphate groups to tyrosine residues in cytoplasmic proteins or the intracellular domains of transmembrane receptors. TK play critical roles in diverse biological functions including cellular processes such as adhesion, motility, proliferation, cell cycle control, cell death, as well as biological functions at the whole-organism level such as growth and development, metabolism or immune defense. TK inhibitors including spleen TK (fostamatinib) and Janus kinases (tofacitinib) inhibitors are two novel oral therapies that have demonstrated short-term good clinical responses in active rheumatoid arthritis patients with and inadequate responses to methotrexate or other traditional (non-biologic) disease-modifying antirheumatic drugs (DMARDs). Those responses are comparable to responses rates from pivotal trials of TNF inhibitors. TK inhibitors are generally well tolerated but not free of adverse effects. Several side effects had been described including gastrointestinal symptoms, neutropenia, hypertension, elevated liver function test and lipid alterations among others. Owing to the limited duration of follow-up of patients treated with TK inhibitors, the long term safety profile of these drugs are unknown.Keywords
This publication has 80 references indexed in Scilit:
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated DiseaseImmunity, 2012
- Focal adhesion kinase and its signaling pathways in cell migration and angiogenesisAdvanced Drug Delivery Reviews, 2011
- Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus‐prone miceArthritis & Rheumatism, 2010
- Genetic deficiency of Syk protects mice from autoantibody‐induced arthritisArthritis & Rheumatism, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- Spleen Tyrosine Kinase Syk Is Necessary for E-Selectin-Induced αLβ2 Integrin-Mediated Rolling on Intercellular Adhesion Molecule-1Immunity, 2007
- Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005